K Liang Zeng1, Arjun Sahgal1, Zain A Husain1, Sten Myrehaug1, Chia-Lin Tseng1, Jay Detsky1, Arman Sarfehnia1, Mark Ruschin1, Mikki Campbell1, Monica Foster1, Sunit Das2, Nir Lipsman3, Georg A Bjarnason4, Eshetu G Atenafu5, Pejman Jabehdar Maralani6, Hany Soliman7. 1. Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON, M4N3M5, Canada. 2. Division of Neurosurgery, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. 3. Division of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. 4. Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. 5. Department of Biostatistics, University Health Network, University of Toronto, Toronto, ON, Canada. 6. Department of Medical Imaging, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. 7. Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON, M4N3M5, Canada. hany.soliman@sunnybrook.ca.
Abstract
PURPOSE: The concept of a radioresistant (RR) phenotype has been challenged with use of stereotactic body radiotherapy (SBRT). We compared outcomes following SBRT to RR spinal metastases to a radiosensitive cohort. METHODS: Renal cell, melanoma, sarcoma, gastro-intestinal, and thyroid spinal metastases were identified as RR and prostate cancer (PCA) as radiosensitive. The primary endpoint was MRI-based local failure (LF). Secondary endpoints included overall survival (OS) and vertebral compression fracture (VCF). RESULTS: From a prospectively maintained database of 1394 spinal segments in 605 patients treated with spine SBRT, 173 patients/395 RR spinal segments were compared to 94 patients/185 PCA segments. Most received 24-28 Gy in 2 fractions (68.9%) and median follow-up was 15.5 months (range, 1.4-84.2 months). 1- and 2-year LF rates were 19.2% and 22.4% for RR metastases, respectively, which were significantly greater (p < 0.001) than PCA (3.2% and 8.4%, respectively). Epidural disease (HR: 2.47, 95% CI 1.65-3.71, p < 0.001) and RR histology (HR: 2.41, 95% CI 1.45-3.99, p < 0.001) predicted for greater LF. Median OS was 17.4 and 61.0 months for RR and PCA cohorts, respectively. Lung/liver metastases, polymetastatic disease and epidural disease predicted for worse OS. 2-year VCF rates were ~ 13% in both cohorts. Coverage of the CTV V90 (clinical target volume receiving 90% of prescription dose) by ≥ 87% (HR: 2.32, 95% CI 1.29-4.18, p = 0.005), no prior spine radiotherapy (HR: 1.96, 95% CI 1.09-3.55, p = 0.025), and a greater Spinal Instability Neoplasia Score (p = 0.013) predicted for VCF. CONCLUSIONS: Higher rates of LF were observed after spine SBRT in RR metastases. Optimization strategies include dose escalation and aggressive management of epidural disease.
PURPOSE: The concept of a radioresistant (RR) phenotype has been challenged with use of stereotactic body radiotherapy (SBRT). We compared outcomes following SBRT to RR spinal metastases to a radiosensitive cohort. METHODS: Renal cell, melanoma, sarcoma, gastro-intestinal, and thyroid spinal metastases were identified as RR and prostate cancer (PCA) as radiosensitive. The primary endpoint was MRI-based local failure (LF). Secondary endpoints included overall survival (OS) and vertebral compression fracture (VCF). RESULTS: From a prospectively maintained database of 1394 spinal segments in 605 patients treated with spine SBRT, 173 patients/395 RR spinal segments were compared to 94 patients/185 PCA segments. Most received 24-28 Gy in 2 fractions (68.9%) and median follow-up was 15.5 months (range, 1.4-84.2 months). 1- and 2-year LF rates were 19.2% and 22.4% for RR metastases, respectively, which were significantly greater (p < 0.001) than PCA (3.2% and 8.4%, respectively). Epidural disease (HR: 2.47, 95% CI 1.65-3.71, p < 0.001) and RR histology (HR: 2.41, 95% CI 1.45-3.99, p < 0.001) predicted for greater LF. Median OS was 17.4 and 61.0 months for RR and PCA cohorts, respectively. Lung/liver metastases, polymetastatic disease and epidural disease predicted for worse OS. 2-year VCF rates were ~ 13% in both cohorts. Coverage of the CTV V90 (clinical target volume receiving 90% of prescription dose) by ≥ 87% (HR: 2.32, 95% CI 1.29-4.18, p = 0.005), no prior spine radiotherapy (HR: 1.96, 95% CI 1.09-3.55, p = 0.025), and a greater Spinal Instability Neoplasia Score (p = 0.013) predicted for VCF. CONCLUSIONS: Higher rates of LF were observed after spine SBRT in RR metastases. Optimization strategies include dose escalation and aggressive management of epidural disease.
Authors: Isabelle Thibault; Eric L Chang; Jason Sheehan; Manmeet S Ahluwalia; Matthias Guckenberger; Moon-Jun Sohn; Samuel Ryu; Matthew Foote; Simon S Lo; Alexander Muacevic; Scott G Soltys; Samuel Chao; Peter Gerszten; Eric Lis; Eugene Yu; Mark Bilsky; Charles Fisher; David Schiff; Michael G Fehlings; Lijun Ma; Susan Chang; Edward Chow; Wendy R Parelukar; Michael A Vogelbaum; Arjun Sahgal Journal: Lancet Oncol Date: 2015-12 Impact factor: 41.316
Authors: Zain A Husain; Arjun Sahgal; Antonio De Salles; Melissa Funaro; Janis Glover; Motohiro Hayashi; Masahiro Hiraoka; Marc Levivier; Lijun Ma; Roberto Martínez-Alvarez; J Ian Paddick; Jean Régis; Ben J Slotman; Samuel Ryu Journal: J Neurosurg Spine Date: 2017-06-09
Authors: Sahra Bodo; Cécile Campagne; Tin Htwe Thin; Daniel S Higginson; H Alberto Vargas; Guoqiang Hua; John D Fuller; Ellen Ackerstaff; James Russell; Zhigang Zhang; Stefan Klingler; HyungJoon Cho; Matthew G Kaag; Yousef Mazaheri; Andreas Rimner; Katia Manova-Todorova; Boris Epel; Joan Zatcky; Cristian R Cleary; Shyam S Rao; Yoshiya Yamada; Michael J Zelefsky; Howard J Halpern; Jason A Koutcher; Carlos Cordon-Cardo; Carlo Greco; Adriana Haimovitz-Friedman; Evis Sala; Simon N Powell; Richard Kolesnick; Zvi Fuks Journal: J Clin Invest Date: 2019-01-14 Impact factor: 14.808
Authors: Chia-Lin Tseng; Hany Soliman; Sten Myrehaug; Young K Lee; Mark Ruschin; Eshetu G Atenafu; Mikki Campbell; Pejman Maralani; Victor Yang; Albert Yee; Arjun Sahgal Journal: Int J Radiat Oncol Biol Phys Date: 2018-07-10 Impact factor: 7.038
Authors: Kyung Hwan Kim; Han Sang Kim; Seung-Seob Kim; Hyo Sup Shim; Andrew Jihoon Yang; Jason Joon Bock Lee; Hong In Yoon; Joong Bae Ahn; Jee Suk Chang Journal: Cancer Res Treat Date: 2021-06-04 Impact factor: 4.679